ROS-Activated Peptide-Based Prodrug for Chemoselective Covalent Targeting in Cancer Cells
- 26 February 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5461-5476
Abstract
The development of covalent drugs has renewed interest in strategies that achieve high selectivity while minimizing off-target reactivity. Herein, we report IRS1, a peptide-based prodrug comprising an integrin-targeting RGD motif, an ROS-responsive thiomorpholine unit, and a chlorambucil-derived covalent warhead for efficient cancer inhibition. Under physiological conditions, IRS1 self-assembles into nanoparticles and preferentially accumulates in uveal melanoma (UM) cells via integrin-mediated targeting. Within the tumor microenvironment, ROS-triggered oxidation of thiomorpholine induces a hydrophobic-to-hydrophilic transition, driving the nanoparticle-to-nanofibril transformation and exposing the chlorambucil moiety. This enables covalent conjugation with the thiol groups of DR4/DR5 on the cell membrane. IRS1 effectively disrupts membrane integrity, activates extrinsic apoptosis, and induces cancer cell death in vitro. In UM xenograft models, IRS1 shows potent antitumor efficacy with reduced systemic toxicity, highlighting a peptide-reconfiguration strategy for tumor-selective covalent therapeutics.Keywords
Funding Information
- Eye Hospital Wenzhou Medical University (KYQD20211003)
- Eye Hospital Wenzhou Medical University (KYQD20211004)
This publication has 59 references indexed in Scilit:
- Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancerActa Pharmaceutica Sinica B, 2024
- Assembly of Glycopeptides in Living Cells Resembling Viral Infection for Cargo DeliveryAngewandte Chemie International Edition, 2024
- Targeting GLUT1 degradation with assembling glycopeptide for cancer inhibitionChemical Engineering Journal, 2024
- Rationally Designed Enzyme‐Resistant Peptidic Assemblies for Plasma Membrane Targeting in Cancer TreatmentAdvanced Healthcare Materials, 2023
- The role of reversible and irreversible covalent chemistry in targeted protein degradationCell Chemical Biology, 2021
- Engineering Gene Therapy: Advances and BarriersAdvanced Therapeutics, 2021
- Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancerClinical and Translational Oncology, 2019
- Filopodia in cell adhesion, 3D migration and cancer cell invasionCurrent Opinion in Cell Biology, 2015
- HER2 expression status in diverse cancers: review of results from 37,992 patientsCancer and Metastasis Reviews, 2015
- Regulation of the actin cytoskeleton in cancer cell migration and invasionBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007